In the Media

AION Labs Launches New AI Startup to Accelerate Identification of Active Small Molecules for Drug Discovery

PR Newswire

New Immuno-Oncology Research Team in Partnership with Ono Pharmaceutical Starts at BioMed X Institute

Pharmiweb

New Immuno-Oncology Research Team in Partnership with Ono Pharmaceutical Starts at BioMed X Institute

Yahoo Finance

BioMed X Start Collaboration in Autoimmunity Research with Servier

BioSpace

BioMed X Start Collaboration in Autoimmunity Research with Servier

MarketWatch

BioMed X hilft Boehringer und expandiert in die USA

Transkript

Das private Forschungsinstitut BioMed X in Heidelberg meldet erfolgreiche Forschungskooperationen mit der Industrie und expandiert in die USA nach New Haven.

BioMed X Launches New US Institute in New Haven, CT

Newsfile

Connecticut Governor Ned Lamont, New Haven Mayor Justin Elicker, and Josh Geballe, Managing Director of Yale Ventures, participated in the launch ceremony of the new BioMed X Institute on Tuesday, June 11, 2024.

BioMed X Launches New US Institute in New Haven, CT

PharmiWeb

The new institute is managed by Mark Johnston, an experienced biotech CEO and entrepreneur. “We are so grateful for all the local support. New Haven is such a vibrant life sciences hub, coming here was the right choice for us,” explains Johnston.

BioMed X Launches New US Institute in New Haven, CT

BioSpace

Connecticut Governor Ned Lamont, New Haven Mayor Justin Elicker, and Josh Geballe, Managing Director of Yale Ventures, participated in the launch ceremony of the new BioMed X Institute on Tuesday, June 11, 2024.

BioMed X Institute: BioMed X Launches New US Institute in New Haven, CT

FinanzNachrichten

BioMed X, an independent research institute founded in Heidelberg, Germany, has expanded its operations with the opening of a new institute in the United States. Located in New Haven, CT, in the vicinity of Yale University, the new facilities are part of the Elm City Bioscience Center.

BIOMED X LAUNCHES NEW US INSTITUTE IN NEW HAVEN, CT

Yale Ventures

Yale Ventures Managing Director Josh Geballe took part in the opening ceremony on Tuesday and expressed his excitement for the collaboration potential that BioMed X brings to New Haven: “Yale is committed to global partnerships that foster innovation. We warmly welcome BioMed X to our bio-ecosystem and are looking forward to future collaborations.”

BioMed X Launches New US Institute in New Haven, CT

Yahoo! Finance

Connecticut Governor Ned Lamont, New Haven Mayor Justin Elicker, and Josh Geballe, Managing Director of Yale Ventures, participated in the launch ceremony of the new BioMed X Institute on Tuesday, June 11, 2024.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

PharmiWeb

The data resulting from this project have been acquired by Boehringer Ingelheim, where this research will be continued, potentially paving the way for novel therapies.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

MarketWatch

The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

FinanzNachrichten

German independent research institute BioMed X announces the successful completion of its second neuroscience project in partnership with Boehringer Ingelheim in the field of psychiatric disorders.

BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project

Yahoo! Finance

The research of BioMed X team EPD – Early Intervention in Psychiatric Diseases – has shed light on the molecular mechanisms underlying white matter deficits in schizophrenia.

BioMed X and AbbVie Extend Research Collaboration in the US

Street Insider

A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.

The BioMed X Institute: New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

FinanzNachrichten

“We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases,” said Carine Boustany, PhD, Global Head of Immunology & Respiratory Diseases Research, Boehringer Ingelheim.

New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg

Yahoo! Finance

XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut.

New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration with Boehringer Ingelheim

PharmiWeb

A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.

New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim

WebDisclosure

BioMed X Institute’s new XSeed Labs research team starts activity in the U.S. in collaboration with Boehringer Ingelheim.